A new prostate cancer treatment has been developed which can not only help patients live longer, but also improve their quality of life.
Trials conducted by The Institute of Cancer Research found that enzalutamide helped men with metastatic castration-resistant prostate cancer survive for 18.4 months.
Patients who were only administered a placebo lived for an average 13.6 months.
In terms of patient comfort, 43 per cent reported that the drug helped them to improve their energy levels and reduced the pain.
"Enzalutamide appears to extend life by around five months, as well as improving quality of life for the patient. So although this isn't a cure, it could offer men crucial extra months to spend with their loved ones" said Elizabeth Woolf, head of Cancer Research UK's information website, CancerHelp UK.
According to the charity, prostate cancer is the most common form of the disease in the UK among men.